Join
Live feed
·
INSIDERFilingvia Quantisnow
PTC Therapeutics Inc. logo

EXEC. VP AND CLO Boulding Mark Elliott sold $489,081 worth of shares (6,347 units at $77.06), decreasing direct ownership by 5% to 111,312 units (SEC Form 4)

ByQuantisnow·Wall Street's wire, on your screen.
PTCT· PTC Therapeutics Inc.
Health Care
Original source

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track PTCT (PTC Therapeutics Inc.) and more on Quantisnow.